194 related articles for article (PubMed ID: 36053908)
61. Cisplatin-loaded core cross-linked micelles: comparative pharmacokinetics, antitumor activity, and toxicity in mice.
Oberoi HS; Nukolova NV; Laquer FC; Poluektova LY; Huang J; Alnouti Y; Yokohira M; Arnold LL; Kabanov AV; Cohen SM; Bronich TK
Int J Nanomedicine; 2012; 7():2557-71. PubMed ID: 22745537
[TBL] [Abstract][Full Text] [Related]
62. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
[TBL] [Abstract][Full Text] [Related]
63. Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.
Wilson AJ; Saskowski J; Barham W; Yull F; Khabele D
J Ovarian Res; 2015 Jul; 8():46. PubMed ID: 26215403
[TBL] [Abstract][Full Text] [Related]
64. Humans have antibodies against a plant virus: evidence from tobacco mosaic virus.
Liu R; Vaishnav RA; Roberts AM; Friedland RP
PLoS One; 2013; 8(4):e60621. PubMed ID: 23573274
[TBL] [Abstract][Full Text] [Related]
65. Bioconjugation Strategies for Tobacco Mild Green Mosaic Virus.
González-Gamboa I; Caparco AA; McCaskill JM; Steinmetz NF
Chembiochem; 2022 Sep; 23(18):e202200323. PubMed ID: 35835718
[TBL] [Abstract][Full Text] [Related]
66. Deposition of platinum clusters on surface-modified Tobacco mosaic virus.
Lee SY; Choi J; Royston E; Janes DB; Culver JN; Harris MT
J Nanosci Nanotechnol; 2006 Apr; 6(4):974-81. PubMed ID: 16736753
[TBL] [Abstract][Full Text] [Related]
67. Nanoparticle-mediated delivery of multinuclear platinum(IV) prodrugs with enhanced drug uptake and the activity of overcoming drug resistance.
Gao Y; Jiang M; Ma Y; Wu S; Li W; Yang X; Li Y; Jing X; Jiang H
Anticancer Drugs; 2016 Feb; 27(2):77-83. PubMed ID: 26473527
[TBL] [Abstract][Full Text] [Related]
68. Tobacco mosaic virus in the lungs of mice following intra-tracheal inoculation.
Balique F; Colson P; Barry AO; Nappez C; Ferretti A; Moussawi KA; Ngounga T; Lepidi H; Ghigo E; Mege JL; Lecoq H; Raoult D
PLoS One; 2013; 8(1):e54993. PubMed ID: 23383021
[TBL] [Abstract][Full Text] [Related]
69. Promotion of Cell Death in Cisplatin-Resistant Ovarian Cancer Cells through KDM1B-DCLRE1B Modulation.
Lee YK; Lim J; Yoon SY; Joo JC; Park SJ; Park YJ
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31108893
[TBL] [Abstract][Full Text] [Related]
70. Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model.
Lee Y; Kollara A; May T; Brown TJ
J Ovarian Res; 2018 Jul; 11(1):56. PubMed ID: 29973223
[TBL] [Abstract][Full Text] [Related]
71. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice.
Cirstoiu-Hapca A; Buchegger F; Lange N; Bossy L; Gurny R; Delie F
J Control Release; 2010 Jun; 144(3):324-31. PubMed ID: 20219607
[TBL] [Abstract][Full Text] [Related]
72. Broad resistance to tobamoviruses is mediated by a modified tobacco mosaic virus replicase transgene.
Donson J; Kearney CM; Turpen TH; Khan IA; Kurath G; Turpen AM; Jones GE; Dawson WO; Lewandowski DJ
Mol Plant Microbe Interact; 1993; 6(5):635-42. PubMed ID: 8274774
[TBL] [Abstract][Full Text] [Related]
73. Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts.
Staffhorst RW; van der Born K; Erkelens CA; Hamelers IH; Peters GJ; Boven E; de Kroon AI
Anticancer Drugs; 2008 Aug; 19(7):721-7. PubMed ID: 18594214
[TBL] [Abstract][Full Text] [Related]
74. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
75. Mechanical stress promotes cisplatin-induced hepatocellular carcinoma cell death.
Ziko L; Riad S; Amer M; Zdero R; Bougherara H; Amleh A
Biomed Res Int; 2015; 2015():430569. PubMed ID: 25685789
[TBL] [Abstract][Full Text] [Related]
76. BLB8, an antiviral protein from Brevibacillus laterosporus strain B8, inhibits Tobacco mosaic virus infection by triggering immune response in tobacco.
Li Y; Jiao Y; Shi J; Xie J; Yin J; Zhao X; Chen H
Pest Manag Sci; 2021 Oct; 77(10):4383-4392. PubMed ID: 33969944
[TBL] [Abstract][Full Text] [Related]
77. RNA Interference towards the Potato Psyllid, Bactericera cockerelli, Is Induced in Plants Infected with Recombinant Tobacco mosaic virus (TMV).
Wuriyanghan H; Falk BW
PLoS One; 2013; 8(6):e66050. PubMed ID: 23824081
[TBL] [Abstract][Full Text] [Related]
78. VEGF antibody plus cisplatin reduces angiogenesis and tumor growth in a xenograft model of ovarian cancer.
Ghosh S; Maity P
J Environ Pathol Toxicol Oncol; 2010; 29(1):17-30. PubMed ID: 20528744
[TBL] [Abstract][Full Text] [Related]
79. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
[TBL] [Abstract][Full Text] [Related]
80. iTRAQ-based protein analysis provides insight into heterologous superinfection exclusion with TMV-43A against CMV in tobacco (Nicotiana benthamiana) plants.
Yang X; Das PP; Oppenheimer P; Zhou G; Wong SM
J Proteomics; 2020 Oct; 229():103948. PubMed ID: 32858166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
